Biomea Fusion (BMEA) vs Intercure (INCR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Biomea Fusion (BMEA) has outperformed Intercure (INCR) over the past year, losing 41.5% versus a loss of 50.6%. Over five years, INCR leads with a -90.9% price change compared with -95.2% for BMEA. Intercure is the larger company by market cap ($42.0 million vs $41.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BMEA | INCR |
|---|---|---|
| Share price | $0.5744 | $3.24 |
| Market cap | $41.75M | $42.03M |
| 1-day change | -2.38% | -7.69% |
| YTD return | -53.68% | -28.79% |
| 1-year return | -41.51% | -50.57% |
| 5-year return | -95.21% | -90.87% |
| EPS (TTM) | $-0.10 | $-0.95 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-61.80M | — |
| 52-week high | $2.24 | $7.55 |
| 52-week low | $0.45 | $3.12 |
| Distance from 52-week high | -74.32% | -57.09% |
| Analyst consensus | buy | — |
| Avg. price target upside | +1118.66% | — |
| Average volume | 2.22M | 15.93K |
| Shares outstanding | 72.68M | 12.97M |
| Employees | 37 | 285 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Biomea Fusion
BMEA stock →Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It's lead clinical program's drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for the treatment of type 2 diabetes.
Health Care · Biotechnology: Pharmaceutical Preparations · 37 employees
About Intercure
INCR stock →InterCure Ltd., together with its subsidiaries, engages in the production, manufacturing, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil.
Health Care · Biotechnology: Pharmaceutical Preparations · 285 employees
BMEA vs INCR FAQ
Which is bigger, Biomea Fusion or Intercure?
Intercure (INCR) is larger, with a market capitalization of $42.03M compared with $41.75M for Biomea Fusion (BMEA).
Which stock has performed better over the past year, BMEA or INCR?
BMEA returned -41.51% over the past 12 months, compared with -50.57% for INCR (price return, excluding dividends). Past performance does not predict future results.
Are Biomea Fusion and Intercure in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.